Relevance of randomised controlled trials in oncologyIan F. Tannock, Francisco Vera-Badillo, Christopher M. Booth et al.|The Lancet Oncology|2016Cited by 116
Synthetic Lethality Interaction Between Aurora Kinases and CHEK1 Inhibitors in Ovarian CancerAna Alcaráz-Sanabria, Alberto Ocaña|Molecular Cancer Therapeutics|2017Cited by 63
Phospho-kinase profile of triple negative breast cancer and androgen receptor signalingMaría D. Cuenca-López, Alberto Ocaña|BMC Cancer|2014Cited by 58
Options to Improve the Action of PROTACs in Cancer: Development of Controlled Delivery NanoparticlesAlberto Juan, Alberto Ocaña|Frontiers in Cell and Developmental Biology|2022Cited by 37
Antitumor activity of the novel multi-kinase inhibitor EC-70124 in triple negative breast cancerMaría D. Cuenca-López, Alberto Ocaña|Oncotarget|2015Cited by 24